Takeda Pharmaceuticals is considering selling some Shire assets if its $62 billion acquisition is approved, Bloomberg reports.
Here's what you should know:
1. Takeda could sell Shire's eye-disease treatment, Xiidra, and its hypoparathyroidism treatment, Natpara.
2. Analysts believe the two drugs could return up to $5 billion if sold.
3. The acquisition is expected to close in March 2019 if approved.